-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the first KPMG China "Biotechnology Innovation 50 Enterprises" selection and release ceremony, hosted by KPMG China and co-organized by China Merchants Securities Co.
KPMG China's "Biotechnology Innovation 50 Enterprises" selection activity has been launched since August 2021.
It has completed the industrial layout of nucleic acids, proteins, instruments, materials and consumables.
It owns automated instruments, biological microspheres, nucleic acid purification, Molecular enzymes, gene synthesis, antibody discovery, protein purification and other core technology platforms, are committed to becoming a leading provider of life science tools and services, realizing independent and controllable R&D and production of key raw materials, and providing a foundation for China and overseas life science industries facilities
.
Winning the first KPMG China "Biotechnology Innovation 50 Enterprises" award in 2022 is a high recognition for the innovative development of Jifan Bio
.
In the future, Jifan will adhere to the mission of "achieving a better life science", focus on the upstream of the life science industry, develop products with high quality, rich variety and stable performance through technology platforms, and provide integrated solutions and technical services for the Customers in IVD, biomedicine, scientific research and other fields create value and help customers develop
.
KPMG China's "Biotechnology Innovation 50 Enterprises" selection activity has been launched since August 2021.
Jifan Bio is a national high-tech biotechnology enterprise integrating R&D, production, sales and technical services.
It has completed the industrial layout of nucleic acids, proteins, instruments, materials and consumables.
It owns automated instruments, biological microspheres, nucleic acid purification, Molecular enzymes, gene synthesis, antibody discovery, protein purification and other core technology platforms, are committed to becoming a leading provider of life science tools and services, realizing independent and controllable R&D and production of key raw materials, and providing a foundation for China and overseas life science industries facilities
.
Winning the first KPMG China "Biotechnology Innovation 50 Enterprises" award in 2022 is a high recognition for the innovative development of Jifan Bio
.
In the future, Jifan will adhere to the mission of "achieving a better life science", focus on the upstream of the life science industry, develop products with high quality, rich variety and stable performance through technology platforms, and provide integrated solutions and technical services for the Customers in IVD, biomedicine, scientific research and other fields create value and help customers develop
.
